Viruses that exclusively infect bacteria. Bacteriophages — phages for short — are the most abundant biological entities on Earth, outnumbering bacteria in most environments by ratios of 1:1 to 10:1. In the human gut, the phageome represents a powerful but underexplored force shaping microbial community structure. Where traditional microbiome research has focused on bacteria, a growing body of evidence reveals that phages act as selective predators capable of driving dysbiosis patterns in diseases ranging from Parkinson's disease to colorectal cancer — and that this predatory activity intersects with metal ecology in ways that are only beginning to be understood.
Phage Biology
Life Cycles
Phages follow three major life cycles, each with different ecological consequences:
- Lytic — The phage hijacks bacterial machinery, replicates, and lyses the host cell to release progeny. This is the "predator" mode that directly reduces bacterial populations.
- Lysogenic (temperate) — The phage integrates its genome into the bacterial chromosome as a prophage, replicating passively with the host. Lysogeny can alter bacterial function through lysogenic conversion — adding virulence factors, metabolic capabilities, or antibiotic resistance genes.
- Chronic — The phage reduces bacterial growth without killing, maintaining a parasitic relationship that shifts competitive dynamics without eliminating the host.
Host Specificity
Phages are typically highly specific, targeting individual bacterial species or even strains. This specificity makes them precision tools — capable of removing specific taxa without disrupting the broader microbial community, unlike broad-spectrum antibiotics.
Phage-Driven Dysbiosis
Parkinson's Disease
The most extensively documented phage-dysbiosis connection involves the gut phageome in parkinsons disease. Lytic phages targeting lactic acid bacteria — particularly Lactococcus — are more than 10-fold enriched in PD gut microbiomes, with corresponding depletion of the targeted bacteria (tetz 2018 parkinsons bacteriophage gut dysbiosis, cross-sectional). This phage-bacterial predator-prey dynamic offers a mechanistic explanation for the selective bacterial depletion observed in PD that cannot be explained by diet or medication alone. The depleted lactic acid bacteria are key producers of short chain fatty acids and contribute to gut barrier integrity; their loss removes metal-buffering capacity and increases free iron, zinc, and manganese availability for metal-tolerant pathogens.
Autism Spectrum Disorder
The ASD gut phageome shows wider diversity and higher abundance than typically developing controls, with significant expansion of Caudoviricetes bacteriophages (shahin 2023 gut phageome asd metagenomics, computational-prediction). Phages infecting Bacteroidaceae and prophages within Faecalibacterium are enriched in ASD, potentially contributing to the depletion of this protective commensal observed across ASD microbiome studies.
Colorectal Cancer and Metabolic Disease
Gut virome alterations are documented in colorectal adenomas (zhang 2025 gut virome premalignant colorectal adenoma), post-surgical CRC recurrence (ho 2024 colorectal cancer virome alterations persistence surgery), and metabolic syndrome (dejonge 2022 gut virome bacteriophage metabolic syndrome). In healthy individuals, prophages (integrated, quiescent) predominate; in disease states, extracellular lytic phage virions increase, suggesting activation of prophages under disease-associated stress.
Phage Therapy
Clinical Evidence
Phage therapy — using phages to target specific pathogenic bacteria — is being explored as an alternative to conventional antibiotics, particularly for multidrug-resistant infections. A systematic review of clinical data (2000-2021) covering 59 studies found phage therapy well tolerated across pneumonia, urology, musculoskeletal, cardiovascular, and dermatological indications (uyttebroek 2022 phage therapy safety efficacy systematic review, systematic-review-meta-analysis). However, no randomized controlled trials were identified, and most evidence derives from case reports and case series. Phage resistance development and neutralizing antiphage antibodies were noted in some cases.
Cardiometabolic Applications
Targeted phage therapy against specific gut bacteria has shown promise in animal models: phages against cytolysin-positive Enterococcus faecalis reduced liver disease in humanized mice, and Klebsiella pneumoniae-targeting phages reduced steatohepatitis inflammation without altering the broader microbiota (wortelboer 2024 phage therapy cardiometabolic diseases, animal-model). Fecal virome transplantation (FVT) — transferring the phage-containing filtrate of fecal matter — can alter gut microbiota composition similarly to full FMT, offering a bacteria-free alternative.
Temperate Phage Engineering
An emerging approach uses temperate phages not to kill bacteria but to alter their function through lysogenic conversion — shifting metabolite production from harmful to beneficial (e.g., increased SCFA production). CRISPR-Cas systems could engineer phages for enhanced specificity.
Connection to Metal Ecology
The intersection of phages and metal ecology remains largely unexplored but mechanistically compelling:
- Phage predation of metal-buffering commensals — Lactic acid bacteria, bifidobacteria, and other commensals bind dietary metals and maintain gut barrier integrity. Their phage-mediated depletion releases metals into the luminal environment, potentially feeding metal-dependent pathogens.
- Prophage induction by metal stress — Environmental stressors including oxidative stress and DNA damage (both downstream of metal toxicity) can trigger prophage induction, converting lysogenic bacteria to lytic phage factories.
- Phage-resistant mutants — Bacteria that survive phage predation often carry surface modifications that also alter metal binding and transport properties.
Key Studies
- tetz 2018 parkinsons bacteriophage gut dysbiosis (cross-sectional) — Foundational study demonstrating >10-fold enrichment of lytic Lactococcus phages in PD gut; proposes phage-driven dysbiosis model.
- uyttebroek 2022 phage therapy safety efficacy systematic review (systematic-review-meta-analysis) — 59-study systematic review confirming phage therapy safety across multiple clinical indications.
- wortelboer 2024 phage therapy cardiometabolic diseases (animal-model) — Reviews phage therapy potential for cardiometabolic diseases; introduces FVT and temperate phage engineering concepts.
- shahin 2023 gut phageome asd metagenomics (computational-prediction) — Demonstrates expanded Caudoviricetes phageome in ASD with Bacteroidaceae-targeting and Faecalibacterium prophage enrichment.
Cross-References
- parkinsons disease — Primary disease model for phage-driven gut dysbiosis
- autism spectrum disorder — Phageome expansion and diversification documented
- colorectal cancer — Virome alterations in adenomas and post-surgical persistence
- dysbiosis — Phage predation as an underexplored driver of microbial imbalance
- gut microbiome — Phageome as the "dark matter" of the gut ecosystem
- short chain fatty acids — Lost when phage predation depletes SCFA-producing commensals
- iron — Freed when metal-buffering commensals are phage-depleted
- antimicrobial resistance — Phage therapy as an alternative to antibiotics for MDR infections